NCT05083169 2026-03-18
MajesTEC-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
Clinical Trials
22 trialsNCT04504825 2026-03-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT04512235 2026-03-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT05257083 2026-03-17
CARTITUDE-6
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT04181827 2026-03-16
CARTITUDE-4
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04923893 2026-03-13
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06158841 2026-03-13
CERVINO
AbbVie
Phase 3 Recruiting
NCT06208150 2026-03-13
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07391657 2026-03-12
DURGA-4
AstraZeneca
Phase 3 Recruiting
NCT05519085 2026-03-11
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT03729804 2026-03-04
(COBRA)
University of Chicago
Phase 3 Active not recruiting
NCT04566328 2026-03-02
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
NCT05572515 2026-02-13
MajesTEC-9
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03710603 2026-02-10
Perseus
European Myeloma Network B.V.
Phase 3 Active not recruiting
NCT00572169 2026-02-05
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
University of Arkansas
Phase 3 Active not recruiting
NCT03617731 2026-02-03
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
University of Heidelberg Medical Center
Phase 3 Active not recruiting
NCT06152575 2026-02-03
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT07297329 2026-01-29
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Sinocelltech Ltd.
Phase 3 Recruiting
NCT01208662 2026-01-22
DFCI 10-106
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT03652064 2026-01-20
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed